Are Intravesical Aminoglycosides the New Gold Standard in the Management of Refractory Urinary Tract Infection: A Systematic Review of Literature

Andrea Ong, Amelia Pietropaolo *, George Brown and Bhaskar K. Somani

University Hospital Southampton NHS Foundation Trust, Tremona Road Southampton, Hampshire SO16 6YD, UK
* Correspondence: ameliapietr@gmail.com

Abstract: Background: Antibiotic resistance in urinary pathogens is increasingly common, leading to rising cases of complicated urinary tract infections. Conventional antimicrobial treatment may be insufficient in these cases and broad-spectrum systemic antibiotics contribute to the problem. Intravesical aminoglycoside instillation is an alternative treatment option that delivers localized and high-dose treatment to the source of infection. This study summarizes the existing evidence for the efficacy and safety of this treatment. Methods: A systematic search was conducted of worldwide literature according to PRISMA methodology and Cochrane standards for systematic review. Studies were included if they reported outcome data for the prevention and reduction in urinary tract infections, eradication of antimicrobial-resistant organisms, or change in sensitivities allowing conventional oral antimicrobial treatment after the administration of intravesical aminoglycoside with or without polymyxin therapy. Results: The search identified 826 articles, of which, 19 were included in the final data analysis and narrative synthesis. A successful outcome was identified in 80.7% (n = 289) of patients treated with aminoglycoside alone and 79.5% (n = 163) treated with an aminoglycoside in combination with polymyxin. Discontinuation was noted in 6.2% of patients. An increase in antimicrobial sensitivity was seen in 15.3% (n = 55) and 16.3% (n = 36) in the aminoglycoside and aminoglycoside/polymyxin groups, respectively. Conclusions: Current evidence supports the use of intravesical aminoglycoside instillation as an efficacious and safe treatment for refractory UTIs. Nevertheless, data is limited, and larger volume studies with longer follow-up periods are required.

Keywords: urinary tract infections; multiresistant infections; novel antimicrobial treatments; UTIs

1. Introduction

The increasing incidence of multi-drug resistant organisms is one of the greatest challenges facing modern medicine. Urinary tract infections are one of the most common reasons for conventional antibiotic prescribing and resistance amongst urinary bacteria is an increasingly significant issue. The availability of effective alternative treatment strategies is therefore imperative, particularly in cases of complicated, refractory, and recurrent infection. One option is intravesical antimicrobial instillations. Existing literature indicates that this could be useful in the treatment and prophylaxis of UTIs, but its true role has yet to be fully established [1,2]. This review will focus on the efficacy of intravesical aminoglycoside instillations (IVA). Research to identify efficacious treatment options is vital in the effort to overcome the significant burden of UTIs on primary and secondary healthcare. Improved management of UTIs will improve the quality of life on an individual level and positively impact the global struggle against growing antimicrobial resistance [3].

2. Methodology

Studies for inclusion in this review were selected according to the following criteria. Inclusion criteria:
• Studies reporting on the administration of intravesical aminoglycosides for the treatment and prevention of refractory UTIs.
• Articles written in the English language.
• All age groups, including pediatric studies.
• Studies with a minimal sample size of three patients.
• Exclusion criteria:
  • Non-human studies, review articles, editorials, guidelines, and case reports.
  • Studies with a non-UTI treatment indication.
  • Studies reporting on non-aminoglycoside intravesical instillations.

2.1. Search Strategy and Study Selection

A systematic review was conducted according to the Cochrane and preferred reporting items for systematic reviews and meta-analyses (PRISMA) standards [4]. An electronic search strategy was performed to find all relevant publications pertaining to intravesical aminoglycoside instillation for the treatment or prophylaxis of UTIs. Databases included AMED, CINAHL, British Nursing Index, Cochrane library, EMBASE, OvidEmcare, HMIC, Medline, PsycINFO, social practice & policy, and science direct/Scopus. References were cross-checked and individual urology journals were hand-searched.

Boolean operators (AND, OR) were used alongside keywords including ‘aminoglycosides’, ‘gentamicin’, ‘neomycin’, ‘nebramycin’, ‘intravesical’, ‘instillation’, ‘irrigation’, ‘recurrent’, ‘UTI’, and ‘urinary tract infection’. The literature search included English articles from inception to May 2022. Eligible studies identified by the search were screened by title and abstract and then by the full text to identify eligible studies.

2.2. Data Extraction and Outcomes of Interest

Data extraction was conducted independently by two authors (A.O. and A.P.) and discrepancies were resolved by mutual consensus. A decision was made to include articles investigating aminoglycosides in conjunction with polymyxin to allow for comparison against the efficacy of aminoglycosides alone. The measure of a successful outcome differed between the studies. Therefore, to aid comparison, this review defined a successful outcome as the prevention of UTI, a $\geq 50\%$ reduction in the rate of UTI, eradication of antimicrobial-resistant organisms, or the change in sensitivities allowing for the oral antimicrobial treatment of UTI. Articles were reviewed for data on method of delivery, follow-up, change in antimicrobial sensitivity, discontinuation of treatment, and antibiotic dose and regime.

3. Results

An initial search identified 826 articles; 32 were selected from an analysis of the title and abstract for full-text review. In total, 3 were excluded as they were case reports with fewer than 3 participants, 2 were systematic reviews, 7 were irrelevant, and 1 was an animal study. After an analysis of the full text, 19 were included in our final review (Figure 1); 12 aminoglycoside and 7 aminoglycoside-polymyxin articles (Tables 1 and 2).

Table 1. Characteristics of studies on the use of intravesical aminoglycoside for UTI.

| Study                 | Study Design | No. of Patients | Mean Age | Male: Female | Additional Risk Factors/Comorbidities | Definition of Recurrent UTI in Included Studies |
|-----------------------|--------------|-----------------|----------|--------------|--------------------------------------|-----------------------------------------------|
| Haldorson et al., 1978 [5] | Prospective  | 53              | ND       | 33:20        | SCI *, multiple sclerosis, vascular disease, and cancer | Recurrent bacteriuria during intermittent catheterization |
| McGuire and Savastano 1987 [6] | Case series  | 4               | 68       | 0:4          | Hemorrhagic cystitis, bladder dysfunction, and high residual volume | Failed response to oral antibiotic treatment |
Table 1. Cont.

| Study                      | Study Design         | No. of Patients | Mean Age | Male:Female | Additional Risk Factors/Comorbidities                                      | Definition of Recurrent UTI in Included Studies |
|----------------------------|----------------------|-----------------|----------|-------------|--------------------------------------------------------------------------|-----------------------------------------------|
| Wan et al., 1994 [7]       | Prospective          | 10              | 1–18 yo  | 4:6         | Myelomeningocele, vesicoureteric reflux, augmentation enterocystoplasty, Crohn’s disease, and renal transplantation | Positive urine cultures                       |
| Arap et al., 2003 [8]      | Retrospective        | 18              | 70       | 0:18        | Recurrent UTI                                                            | Failed response to oral antibiotic treatment   |
| Defoor et al., 2006 [9]    | Retrospective        | 80              | 10       | 38:42       | Neurogenic bladder, bladder extrophy, cloacal anomalies, Hinman syndrome, vesicoureteral reflux, hypospadias, posterior urethral valves, bladder reconstruction, and renal transplantation | Failed response to oral antibiotic treatment   |
| Praba and Utomo 2015 [10]  | Prospective clinical trial | 28             | 58.9     | 54:2        | Benign prostatic hyperplasia and prostate carcinoma                      | Nosocomial catheter-associated UTIs           |
| Abrams et al., 2017 [11]   | Retrospective        | 27              | 55       | 7:20        | Neobladders, neurogenic bladder, ileocystoplasty, and ISC **             | Recurrent UTI, failed oral prophylaxis         |
| Cox et al., 2017 [11]      | Prospective          | 22              | 37.5     | 22:15       | SCI, multiple sclerosis, and myelodysplasia transverse myelitis          | Four UTIs in the preceding 6-month period      |
| Dray VE et al., 2017 [12]  | Retrospective        | 22              | ND       | ND          | ISC                                                                      | Three or greater urinary tract infections (UTIs) in one year, or two or more UTIs in six months |
| Stalenhoef et al., 2019 [13]| Retrospective        | 63              | 61       | 51:12       | ISC, chronic bacterial prostatitis, vesicoureteral reflux, and neobladder | Recurrent UTIs despite failed oral prophylaxis |
| Chernyak and Salamon 2020 [14] | Retrospective case series | 12             | 80.3     | 00:12       | Neurogenic bladder and structurally abnormal urinary tract               | Two UTIs in 6 months or three UTIs in a 1 year period |
| Marei et al., 2021 [15]    | Retrospective        | 24              | 3.8      | 13:11       | Neurogenic bladder, bladder extrophy, cloacal anomalies, and posterior urethral valves | Recurrent UTIs despite failed oral prophylaxis |

* Spinal cord injury (SCI). ** Intermittent self-catheterization (ISC). Not disclosed (ND).

Figure 1. Diagram showing the PRISMA flowchart of studies searched, reviewed, and included in the systematic review.
Table 2. Characteristics of studies on the use of an intravesical aminoglycoside in combination with polymyxin for UTI.

| Study                        | Study Design            | No. of Patients | Mean Age | Male: Female | Additional Risk Factors/Comorbidities | Definition of Recurrent UTI               |
|------------------------------|-------------------------|-----------------|----------|--------------|--------------------------------------|------------------------------------------|
| Pearman et al., 1988 [16]    | Prospective randomized comparative | 18              | 26       | 18:0         | SCI                                  | Consecutive positive urinary cultures    |
| Pearman 1979 [17]            | Randomized control trial | 22              | 30       | 17:5         | SCI                                  | Consecutive positive urinary cultures    |
| Linsenmeyer et al., 1998 [18]| Retrospective           | 12              | ND       | 7:3          | SCI                                  | Culture-positive UTIs unable to be managed with oral antibiotics |
| Anderson 1980 [19]           | Randomized prospective  | 17              | ND       | 64:0         | Acute neurogenic bladder             | Significant bacteriuria                  |
| Waites et al., 2006 [20]     | Randomized              | 30              | ND       | ND           | SCI and neurogenic bladder           | Recurrent microscopic bacteriuria and pyuria |
| Rhame and Perkash 1979 [21]  | Retrospective           | 70              | 36.4     | 70:0         | SCI                                  | Positive urine culture                   |
| Huen et al., 2019 [22]       | Retrospective           | 52              | 14.5     | 21:31        | Spina bifida, cloacal extrophy, posterior urethral valves, appendicovesicostomy, and enterocystoplasty | Frequent symptomatic UTIs despite oral antibiotic prophylaxis |

A total of 584 patients were included in the systematic review. The mean age was 35 years. The gender demographics of participants were not included in two studies, and of those listed, 222 were male and 162 were female. In summary, 10 studies assessed the efficacy of gentamicin, 3 studies treated gentamicin-resistant patients with amikacin, tobramycin, or garamycin, and 2 studies assessed netilmicin and neomycin. Seven studies assessing the use of an intravesical aminoglycoside in combination with polymyxin were included for comparison. All the studies were observational, apart from two randomized control trials comprising 52 participants [17,20].

The indication for the use of IVA was a mixture of treatment and prophylaxis of refractory UTIs. Underlying pathology included intermittent self-catheterization/long-term catheterization, recurrent UTIs, prostate carcinoma, benign prostate hyperplasia, and urinary diversion. The most common underlying pathology identified was neurogenic bladder (listed in 74% of papers).

3.1. Clinical Efficacy of IVA

A successful outcome was identified in 80.7% (n = 289) of the patients in the papers assessing the use of aminoglycoside alone. A total of 79.5% (n = 163) of successful outcomes were measured in the papers evaluating treatment with an aminoglycoside in combination with polymyxin (Tables 3 and 4).

Table 3. Administration, outcomes, and safety of use of intravesical aminoglycosides for UTI.

| Study                        | Intervention                      | Follow-Up (Range) | Successful Outcome ** | Discontinued Treatment | Side Effects | Serum Level | Change in Sensitivities | Developed New Resistance |
|------------------------------|-----------------------------------|-------------------|-----------------------|------------------------|--------------|-------------|-------------------------|--------------------------|
| Haldorson et al., 1978 [5]   | 0.1% neomycin solution            | 6 weeks           | 25/53                 | 0                      | ND           | ND          | ND                      | 37/53                    |
| McGuire and Savastano 1987 [6]| 20 mL of 240 mg gentamicin in 1 L 0.9% NaCl * | 20 months (3–36 months) | 4/4                   | 0                      | ND           | ND          | ND                      | ND                       |
| Wan et al., 1994 [7]         | 30–60 mL 480 mg gentamicin in 1 L 0.9% NaCl | 1 week            | 10/10                 | 0                      | Yes, negligible | ND          | ND                      | ND                       |
### Table 3. Cont.

| Study                        | Intervention                                      | Follow-Up (Range) | Successful Outcome ** | Discontinued Treatment | Side Effects | Serum Level | Change in Sensitivities | Developed New Resistance |
|------------------------------|----------------------------------------------------|-------------------|-----------------------|------------------------|--------------|-------------|------------------------|--------------------------|
| Arap et al., 2003 [8]        | 480 mg gentamicin in 1 L 0.9% NaCl + 100 mL sodium carbonate | 65.1 months       | 12/18                 | 3/18                   | 3 UTI        | Yes, negligible | 0                      | 3/18                     |
| Defoor et al., 2006 [9]      | 0.48 mg/mL gentamicin in 30 mL 0.9% NaCl           | 90 days           | 75/80                 | Variable not trackable | Minor rise in serum creatinine for three patients with chronic renal insufficiency | Yes, negligible | 16/80                  | 5/80                     |
| Praba and Utomo 2015 [10]    | 25 mg/1 mL netilmicin in 50 mL 0.9% NaCl          | 4 days            | 22/28                 | 0                      | ND           | ND          | ND                     | ND                       |
| Abrams et al., 2017 [3]      | 80 mg gentamicin in 10 mL 0.9% NaCl                | 26 months (2-67)  | 22/27                 | 6/27                   | 0            | Yes, negligible | 18/27                  | 1/27                     |
| Cox et al., 2017 [11]        | 14.4–28.8 mg gentamicin in 30–60 mL of 0.9% NaCl (according to bladder capacity) | 6 weeks           | 22/22                 | 0                      | 1 yeast infection, 1 diarrhea | Not checked | 9/22                   | 8/22                     |
| Dray VE et al., 2017 [12]    | 14.4–28.8 mg gentamicin in 30–60 mL of 0.9% NaCl (according to bladder capacity) | ND                | 22/22                 | ND                     | 0            | Yes, negligible | ND                     | ND                       |
| Stalenhoef et al., 2019 [15] | 80 mg gentamicin in 20 mL of 0.9% NaCl             | 42 weeks (6–148)  | 52/63                 | 10                     | Hearing loss (n = 2), vaginal discomfort (n = 10), and abdominal discomfort (n = 3) | Yes, negligible | 4/14                   | 6/63                     |
| Chernyak and Salamon 2020 [14] | 80 mg gentamicin in 60 mL 0.9% NaCl or 80 mg tobramycin in 100 mL 0.9% NaCl | 6 months         | 12/12                 | 0                      | 0            | Not checked | 8/12                   | 0/12                     |
| Marei et al., 2021 [15]      | 8 mg gentamicin in 20 mL 0.9% NaCl or 20 mg Gent in 50 mL 0.9% NaCl (per bladder capacity) | 3 years           | 11/19                 | 1                      | ND           | One detectable | ND                     | 1/24                     |

* Sodium Chloride (NaCl). ** Successful outcome defined as the prevention of UTI, a ≥ 50% reduction in the rate of UTI, eradication of antimicrobial-resistant organisms, or the change in sensitivities allowing for the oral antimicrobial treatment of UTI.

### Table 4. Administration, outcomes, and safety of use of an intravesical aminoglycoside in combination with polymyxin for UTI.

| Study                        | Intervention                                      | Follow-Up | Successful Outcome ** | Discontinued Treatment | Side Effects | Serum Level | Change in Sensitivities | Developed New Resistance |
|------------------------------|----------------------------------------------------|-----------|-----------------------|------------------------|--------------|-------------|------------------------|--------------------------|
| Pearman et al., 1988 [16]    | 150 mg kanamycin + 30 mg colistin in 25 mL sterile water | 130 days  | 2/7                   | ND                     | 0            | ND          | ND                     | ND                       |
| Pearman 1979 [17]            | kanamycin 150 mg + colistin 30 mg in 25 mL sterile water | 120 days  | 9/17                  | ND                     | ND           | ND          | ND                     | ND                       |
| Study                        | Intervention                                      | Follow-Up | Successful Outcome ** | Discontinued Treatment | Side Effects                     | Serum Level | Change in Sensitivities | Developed New Resistance |
|------------------------------|---------------------------------------------------|-----------|-----------------------|------------------------|----------------------------------|-------------|-------------------------|--------------------------|
| Linsenmeyer et al., 1998 [18]| 30 mL neomycin/polymyxin solution                 | 6 months  | 9/12                  | 2/12                   | Allergy                          | ND          | 9/12                    | 3/12                     |
| Anderson 1980 [19]           | 30 mL 160 mg neomycin, 800,000 polymyxin-B in sterile water | ND        | 17/17                 | ND                     | ND                               | ND          | ND                      | ND                       |
| Waites et al., 2006 [20]     | 30 of 40 mg/mL neomycin sulfate and 200,000 units/mL polymyxin B | 8 weeks   | 23/30                 | 8/30                   | Autonomic dysreflexia (n = 2)     | ND          | 12/30                   | 18/30                    |
| Rhame and Perkash 1979 [21]  | 50 mL of 120 ug/mL neomycin and 60 ug/mL polymyxin B | 28 months | 51/70                 | ND                     | ND                               | ND          | 1/70                    | ND                       |
| Huen et al., 2019 [22]       | 30–50 mL 480 mg gentamicin in 1 L 0.9% NaCl       | 6 months  | 52/52                 | 6/52                   | ND                               | ND          | 14/52                   | 0                        |

** Successful outcome defined as the prevention of UTI, a ≥50% reduction in the rate of UTI, eradication of antimicrobial-resistant organisms, or the change in sensitivities allowing for the oral antimicrobial treatment of UTI.

3.2. Patient Compliance

The majority of the IVA administrations were undertaken by the patients themselves or their parents (63.2%, 12 out of 19 papers) [3,6,7,9,11–15,20–22]. The dosage of aminoglycoside (concentration of aminoglycoside, volume of aminoglycoside, and frequency of administration) varied greatly between studies. However, there was no significant association between dosage and discontinuation of treatment or development of new antimicrobial resistance. In total, 36 cases of discontinuation were noted (6.2%). Reasons for discontinuation included allergy, UTI, “clinical failure”, chronic prostatitis, “other health-related issues”, stones, pregnancy, chemotherapy, surgery (including cystectomy, nephrectomy, and bladder stone), and one case of newly developed gentamicin resistance.

3.3. Safety

An increase in antimicrobial sensitivity was observed in 15.3% (n = 55) and 16.3% (n = 36) in the aminoglycoside and aminoglycoside/polymyxin groups, respectively (Tables 3 and 4).

Amongst these patients, oral antibiotics were used rather than intravenous antibiotics, which reduced UTI-related hospital admissions. New antimicrobial resistance was reported in 14.0% (n = 82) of patients; 10.4% (n = 61) in the aminoglycoside group and 3.6% (n = 21) in the aminoglycoside/polymyxin group.

One case of an elevated serum level of gentamicin was noted by Marei et al. [15]. No consequent side effects, including renal impairment or ototoxicity, were reported. Side effects were observed in 4.6% (n = 27) of patients. Renal impairment was reported in three patients. However, this was attributed to a known background of chronic renal insufficiency [9]. Stalenhoef et al. identified hearing loss in two patients [13]. Once again, this was attributed to pre-existing co-morbidities rather than aminoglycoside-induced ototoxicity. Other reported side effects included UTI, vaginal discomfort, yeast infection, diarrhea, allergic reaction, and autonomic dysreflexia.

4. Discussion

Localized, high-concentration IVA treatment aims to effectively eradicate multi-resistant organisms and limit growing antimicrobial resistance through the avoidance of broad-spectrum intravenous antibiotics [2]. This summary of the available literature supports
existing evidence that the use of IVA is safe and successful in patients at risk of developing UTIs. Our definition of a successful outcome incorporated various parameters to allow for the comparison between different methodologies and measured outcomes. A successful outcome in the form of a reduction in UTI and/or reduced sensitivity allowing for oral antibiotic therapy was seen in both the aminoglycoside (82.1%) and aminoglycoside/polymyxin (79.5%) treatment groups.

Whilst the studies differ in duration of follow-up, findings consistently suggest that IVA has a role in the management of UTIs in the short term. Over a six-month period of review, Chernyak et al. found a statistically significant reduction in the incidence of UTIs from 2.5 to 1.5 per 6 months \( (p = 0.025) \) [14]. The study by Stalenhoef et al. explored a longer follow-up period of 42 weeks. While eradication of UTIs was observed in 41% of patients, 82% of the samples noted a 50% reduction in the rate of UTI, and only 8% of breakthrough UTIs required treatment with intravenous antibiotics [13]. Assessing a longer period of follow-up (an average of 26 months), Abrams et al. observed a reduction in UTIs in 22 out of 27 patients [3]. The reliability of these findings is limited by the relatively short periods of patient follow-up. Further research should aim to assess the long-term impact of IVA in terms of efficacy, safety, and patient satisfaction.

Complications such as ototoxicity and nephrotoxicity are well established with the use of high-dose aminoglycosides [23]. Intravesical administration aims to reduce drug toxicity by utilizing the tough impermeable nature of the urothelium to limit systemic absorption [24]. Despite the use of high concentrations of IVA, this review shows no evidence of systemic absorption of aminoglycoside. This suggests that a high-dose localized IVA can be safely used without systemic complications. However, these findings are limited as several of the studies did not include data on the serum level of aminoglycoside and associated side effects [5,6,11,14,16–22].

The low discontinuation rate of 6.2% and the high proportion of patients self-administering IVA suggests that patients were agreeable to this method of drug administration. Reducing the burden of staff required to administer the medication increases patient accessibility for IVA. Low complication rates (4.6%) and good patient compliance with the treatment suggest that IVA treatment is not only efficacious but a well-tolerated method of treatment for patients.

An improvement in antimicrobial sensitivity was observed from data collected from 10 papers. Although this was only a small percentage (15.3% \( (n = 55) \) and 16.3% \( (n = 36) \) in the aminoglycoside and aminoglycoside/polymyxin groups, respectively), this was a promising finding in the endeavor to reduce antimicrobial resistance. Increased antimicrobial susceptibility broadens the range of treatments available to these patients. This could avoid hospital admission, reduce the incidence of complications associated with hospital admission, and improve quality of life [3]. Chernyak et al. reported a statistically significant reduction in microorganism resistance from the median resistance of 8.5 antibiotics in a profile to 0 \( (p = 0.065) \) [14]. Overall, new antimicrobial resistance was reported in 14.0% \( (n = 82) \) of patients; 10.4% \( (n = 61) \) in the aminoglycoside group and 3.6% \( (n = 21) \) in the aminoglycoside/ polymyxin group. It was not possible to identify a trend between IVA and antimicrobial sensitivity based on our findings. Further studies should assess the long-term impact of IVA on antimicrobial resistance both in the treatment and the prophylaxis of UTIs.

Limitations and Areas of Future Research

Most of the data included were retrospective and therefore vulnerable to bias and unable to be generalized across various healthcare settings. Most of the papers in the aminoglycoside group assessed the efficacy of gentamicin. However, the aminoglycoside used varied between studies and even within studies in some cases due to resistance. The reliability of the findings is therefore limited by inconsistent outcome measures between papers. For example, only 10 of the included papers included data on antimicrobial sensitivity, and only 8 papers reported on the serum level of aminoglycoside. Due to these data insufficiencies, definitive conclusions cannot be drawn. Additionally, although the
The majority of patients had a neurogenic bladder as the underlying pathology, there was great variation in the inclusion criterion between papers.

The review is limited by the heterogeneity of the studies and variation in sample sizes. Variability in study design was noted in the definition of recurrent/refractory UTI, the measure of successful outcomes, the categorization of groups into treatment versus prophylactic IVA, and the duration of follow-up. As a result of these key design differences, it was not possible to accurately evaluate the merits or failures of IVA treatment amongst these patients (Tables 1 and 2).

The short follow-up in some studies prevents the true assessment of success in these patients. Five of thirteen papers are characterized by a short follow-up duration. Haldorson et al., Wan et al., Praba et al., and Cox and Waites et al. describe a follow-up that goes from a minimum of 4 days to a maximum of 8 weeks (6, 10, 12, 19, 24). Given that the definition of recurrent UTIs is \( \geq 2 \) infections in six months or \( \geq 3 \) infections in one year, UTI resolution should be defined with a longer follow-up after the treatment. However, in view of limited patient numbers and poor patient compliance to long-term follow-up, these papers were also included.

Future studies with a more robust methodology and longer follow-ups are required to draw meaningful conclusions. This would allow for a more accurate assessment of treatment efficacy with a view to aid clinical guidelines. It was noted the patient demographics were often not disclosed or sparsely documented in the included papers. This could be explored further to evaluate the optimum demographic characteristics of patients that would benefit from IVA and evaluate the impact of patient co-morbidity.

5. Conclusions

This study observed that IVA is an efficacious method of managing the treatment and prophylaxis of refractory UTIs in the short term. The intravesical method of administration allows for higher concentrations of aminoglycoside to be given in a localized approach with no systemic absorption of aminoglycoside or associated side effects. Patients were able to self-administer the treatment and the low discontinuation rates suggest that it is a well-tolerated treatment option. Further research with larger sample sizes, longer follow-up periods, and analysis of trends in antimicrobial susceptibility will better assess the efficacy of IVA for the treatment and prophylaxis of UTIs.

Author Contributions: Conceptualization, A.O. and A.P.; methodology, B.K.S.; software A.O.; validation, B.K.S.; formal analysis A.O.; investigation, A.O. and G.B.; resources, not needed; data curation, A.O.; writing—original draft preparation, A.O.; writing—review and editing, A.O. and G.B.; visualization, A.P.; supervision, A.P.; project administration, A.P.; funding acquisition, no fund required. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Pietropaolo, A.; Jones, P.; Moors, M.; Birch, B.; Somani, B.K. Use and Effectiveness of Antimicrobial Intravesical Treatment for Prophylaxis and Treatment of Recurrent Urinary Tract Infections (UTIs): A Systematic Review. *Curr. Urol. Rep.* 2018, 19, 78. Available online: https://pubmed.ncbi.nlm.nih.gov/30094687/ (accessed on 30 June 2022). [CrossRef]

2. Van Nieuwkoop, C.; den Exter, P.L.; Elzevier, H.W.; den Hartigh, J.; van Dissel, J.T. Intravesical gentamicin for recurrent urinary tract infection in patients with intermittent bladder catheterisation. *Int. J. Antimicrob. Agents* 2010, 36, 485–490. Available online: https://pubmed.ncbi.nlm.nih.gov/20580533/ (accessed on 30 June 2022). [CrossRef] [PubMed]

3. Abrams, P.; Hashim, H.; Tomson, C.; Macgowan, A.; Skews, R.; Warren, K. The use of intravesical gentamicin to treat recurrent urinary tract infections in lower urinary tract dysfunction. *Neurourol. Urodyn.* 2017, 36, 2109–2116. [CrossRef]
4. Higgins, J.P.T. (Ed.) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011. Available online: http://handbook.cochrane.org; https://www.google.com/search?q=Higgins%2C+JPT%2C+Handbook%2C+5.1.0%2C+2011%2C+The+Cochrane+Collaboration%2C+2011+(accessed on 30 June 2022).

5. Haldorsen, A.M.; Keys, T.F.; Maker, M.D.; Opitz, J.L. Nonvalue of Neomycin Instillation after Intermittent Urinary Catheterization. Antimicrob. Agents Chemotherapy 1978, 14, 368–370. [CrossRef] [PubMed]

6. McGuire, E.J.; Savastano, J.A. Treatment of intractable bacterial cystitis with intermittent catheterization and antimicrobial instillation: Case report. J. Urol. 1987, 137, 495–496. Available online: https://pubmed.ncbi.nlm.nih.gov/3820384/ (accessed on 30 June 2022). [CrossRef]

7. Wan, J.; Kozminski, M.; Wang, S.C.; Faerber, G.J.; McGuire, E.J.; Bloom, D.A.; Ritchey, M.L. Intravesical instillation of gentamicin sulfate: In vitro, rat, canine, and human studies. Urology 1994, 43, 531–536. Available online: https://pubmed.ncbi.nlm.nih.gov/8154077/ (accessed on 30 June 2022). [CrossRef]

8. Arap, M.P. Efficacy of Intravesical Gentamicin Sulfate Solution for Recalcitrant Recurrent Cystitis in Women. Infect. Urol. 2003, 16. Available online: https://www.researchgate.net/publication/313168378_Efficacy_of_intravesical_intralesional_gentamicin_sulfate_solution_for_recalcitrant_recurrent_cystitis_in_women (accessed on 22 June 2022).

9. Defoor, W.; Ferguson, D.; Mashni, S.; Creelman, L.; Reeves, D.; Minevich, E.; Reddy, P.; Sheldon, C. Safety of Gentamycin Bladder Irrigations in Complex Urological Cases. J. Urol. 2006, 175, 1861–1864. [CrossRef] [PubMed]

10. Praba, B.A.; Utomo, T. Efficacy of intravesical instillation of netilmicin on managing uti. Indones J. Urol. 2015, 22. [CrossRef]

11. Cox, L.; He, C.; Bevins, J.; Clemens, J.Q.; Stoffel, J.T.; Cameron, A.P. Gentamicin bladder instillations decrease symptomatic urinary tract infections in neurogenic bladder patients on intermittent catheterization. Can. Urol. Assoc. J. 2017, 11, E350–E354. Available online: https://pubmed.ncbi.nlm.nih.gov/29382457/ (accessed on 30 June 2022). [CrossRef] [PubMed]

12. Dray, E.V.; Clemens, J.Q. Recurrent urinary tract infections in patients with incomplete bladder emptying: Is there a role for intravesical therapy? Transl. Androl. Urol. 2017, 6 (Suppl. 2), S163. [CrossRef] [PubMed]

13. Stalenhoef, J.E.; Van Nieuwkoop, C.; Menken, P.H.; Bernards, S.T.; Elzevier, H.W.; Van Dissel, J.T. Intravesical Gentamicin Treatment for Recurrent Urinary Tract Infections Caused by Multidrug Resistant Bacteria. J. Urol. 2019, 201, 549–555. Available online: https://pubmed.ncbi.nlm.nih.gov/30316898/ (accessed on 30 June 2022). [CrossRef] [PubMed]

14. Chernyak, S.; Salamon, C. Intravesical Antibiotic Administration in the Treatment of Recurrent Urinary Tract Infections: Promising Results From a Case Series. Female Pelvic Med. Reconstr. Surg. 2020, 26, 152–154. Available online: https://pubmed.ncbi.nlm.nih.gov/31990805/ (accessed on 30 June 2022). [CrossRef]

15. Marei, M.M.; Jackson, R.; Keene, D.J.B. Intravesical gentamicin instillation for the treatment and prevention of urinary tract infections in complex paediatric urology patients: Evidence for safety and efficacy. J. Pediatr. Urol. 2021, 17, e1–e65. [CrossRef] [PubMed]

16. Pearman, J.W.; Bailey, M.; Harper, W.E.S. Comparison of the efficacy of “Trisdine” and kanamycin-colistin bladder instillations in reducing bacteriuria during intermittent catheterisation of patients with acute spinal cord trauma. Br. J. Urol. 1988, 62, 140–144. Available online: https://pubmed.ncbi.nlm.nih.gov/3136820/ (accessed on 15 June 2022). [CrossRef]

17. Pearman, J.W. The value of kanamycin-colistin bladder instillations in reducing bacteriuria during intermittent catheterisation of patients with acute spinal cord injury. Br. J. Urol. 1979, 51, 367–374. Available online: https://pubmed.ncbi.nlm.nih.gov/533594/ (accessed on 30 June 2022). [CrossRef]

18. Linsenmeyer, T.A.; Jain, A.; Thompson, B.W. Effectiveness of Neomycin/Polymyxin Bladder Irrigation to Treat Resistant Urinary Pathogens in Those with Spinal Cord Injury. J. Spinal Cord. Med. 1998, 22, 252–257. [CrossRef]

19. Anderson, R.U. Prophylaxis of bacteriuria during intermittent catheterization of the acute neurogenic bladder. J. Urol. 1980, 123, 364–366. Available online: https://pubmed.ncbi.nlm.nih.gov/6244414/ (accessed on 30 June 2022). [CrossRef]

20. Waites, K.B.; Canupp, K.C.; Roper, J.F.; Camp, S.M.; Chen, Y. Evaluation of 3 Methods of Bladder Irrigation to Treat Bacteriuria in Persons With Neurogenic Bladder. J. Spinal. Cord. Med. 2006, 29, 217. [CrossRef]

21. Hame, F.S.; Perkash, I. Urinary tract infections occurring in recent spinal cord injury patients on intermittent catheterization. J. Urol. 1979, 122, 669–673. Available online: https://pubmed.ncbi.nlm.nih.gov/501823/ (accessed on 30 June 2022). [CrossRef]

22. Huen, K.H.; Nik-Ahd, F.; Menken, P.H.; Bernards, S.T.; Elzevier, H.W.; Van Dissel, J.T. Intravesical gentamicin sulfate solution decreases symptomatic urinary tract infections in neurogenic bladder patients on clean intermittent catheterization. Br. J. Urol. 1987, 57, 495–496. Available online: https://pubmed.ncbi.nlm.nih.gov/3820384/ (accessed on 30 June 2022). [CrossRef] [PubMed]

23. Block, M.B.D. Aminoglycosides. In StatPearls Treasure Island; The Royal Manchester Children’s Hospital, Manchester University NHS Foundation Trust: Manchester, UK, 2022. Available online: https://www.google.com/search?q=Block%2C+M%252C+Blanchard%2C+D.%26a=timeline%3D+2021%2Bupdated%2B2021%2B+Jtil+23%252BD.%2BIn%2523%2BStatPearls%2B+25%2B+Treasure%2BIsland%2B(FL)%252A%2BStatPearls%2B+Publishing%2B2021%2B+Jan.+-%2B+Available+from+%2B%2BTable%2Btreasure_island%2Bbooks%2B25 (accessed on 30 June 2022).

24. Tyagi, P.; Wu, P.C.; Chancellor, M.; Yoshimura, N.; Huang, L. Recent advances in intravesical drug/gene delivery. Mol. Pharm. 2006, 3, 369–379. [CrossRef] [PubMed]